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Abstract
Background: Intermittent preventive treatment for prevention of malaria in pregnancy (IPTp) is
a key component of malaria control strategy in Nigeria and sulfadoxine-pyrimethamine (SP) is the
drug of choice. Despite the evidence of the effectiveness of IPTp strategy using SP in reducing the
adverse effects of malaria during pregnancy the uptake and coverage in Nigeria is low. This study
set out to assess the use of IPTp among pregnant women attending primary health centres in the
rural area and determine factors that influence the uptake.
Methods: A cross-sectional study was carried out between July and August 2007 among 209
pregnant women selected by systematic random sampling from antenatal care attendees at primary
health care in a rural Local Government Area of Ekiti State, Nigeria. Information on knowledge of
IPT, delivery, adherence and acceptability was obtained using an interviewer administered
questionnaire. Descriptive statistics such as means, range, proportions were used. Chi-square test
was used to examine association between categorical variables. All analyses were performed at 5%
level of significance.
Results: One hundred and nine of 209 (52.2%) respondents have heard about IPTp but only 26
(23.9%) were able to define it. Fifty seven (27.3%) reported to have received at least one dose of
IPTp during the index pregnancy and all were among those who have heard of IPTp (52.3%).
Twenty one of the 57 (36.8%) took the SP in the clinic. Only three of the twenty-one (14.3%) were
supervised by a health worker. Twenty two of the 36 women (61.1%) who did not take their drugs
in the clinic would have liked to do so if allowed to bring their own drinking cups. Almost half
(43.9%) of those who had used IPTp during the index pregnancy expressed concern about possible
adverse effect of SP on their pregnancies. Periodic shortages of SP in the clinics were also reported.
Conclusion: In this study, IPTp use among pregnant women was very low and there was poor
adherence to the Directly Observed Therapy (DOT) scheme. Concerted effort should be made to
increase awareness of IPTp among the public especially women of child bearing age. Health workers
should also be trained and monitored to ensure adherence.
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Background
Each year, more than 30 million African women in
malaria endemic areas become pregnant and are at risk of
infection with Plasmodium falciparum [1,2]. This results in
high prevalence of patent parasitemia and clinical malaria
[3,4] in pregnancy. In southwest Nigeria, past studies
reported malaria parasite prevalence of between 60% and
72% among pregnant women [4,5]. Malaria during preg-
nancy causes up to 10,000 maternal deaths each year and
contributes to high rates of maternal morbidity including
fever and severe anemia, especially in first time mothers
[6,7]. It is also a cause of low birth weight and placental
parasitaemia [8,9]. Between 75,000 to 200,000 infant
deaths annually are attributable to malaria infection in
pregnancy [10,11]. A recent study estimated that malaria
may contribute to 3–5% of maternal anaemia, 8–14% of
low birth weight (LBW) and 3–8% of infant mortality
[10]. The harmful impact of malaria is most apparent in
the first and second pregnancies of most pregnant women
living in areas of relatively stable transmission [1].
Prevention of malaria in pregnancy is a major public
health challenge and a priority for the Roll Back Malaria
(RBM) Partnership. In high transmission areas including
Nigeria, the RBM partnership recommends a three
pronged approach for reducing the burden of malaria
among pregnant women [11-13]. These are effective case
management of malaria infection, use of insecticide
treated nets (ITN) and intermittent preventive treatment
(IPTp) in areas of stable transmission. In line with this rec-
ommendation, approach to prevention of malaria in preg-
nancy changed since the early 2000's, moving from a
weekly or bimonthly chemoprophylaxis to intermittent
preventive treatment (IPTp) and insecticide-treated bed
nets (ITNs) [11]. Nigeria adopted the IPT strategy in year
2005 [13,14].
IPTp consists of administration of curative dose of an effi-
cacious anti-malarial drug at least twice during the second
and third trimesters of pregnancy during routinely sched-
uled antenatal clinic visits regardless of whether the
woman is infected or not [9,15,16]. The drug is adminis-
tered under supervision during antenatal care visits. Sulf-
adoxine-pyrimethamine (SP) is the drug currently
recommended for the IPT strategy [11,14]. It has a good
safety profile and remains a good option for IPTp in
endemic areas in Africa [17,14]. The current National
Malaria Treatment Guideline and Policy in Nigeria recom-
mends SP as first line agent for IPTp and quinine for treat-
ment of clinical malaria in all trimesters, Artemisinin
based combination therapy (ACT) is considered safe sec-
ond line agents in the second and third trimesters [12,13]
and may be used in first trimester where there are no suit-
able alternatives [12]. In addition, ACT is recommended
for treatment of uncomplicated malaria for the general
populace following the development of resistance to chlo-
roquine and SP.
IPTp with SP has been shown to reduce the risk of mater-
nal anemia, placental parasitaemia and low birth weight
[8,18,19]. In a study carried out in Ibadan, southwest
Nigeria, IPTp-SP was found to be highly effective in pre-
venting maternal and placental malaria among parturient
women as well as in improving pregnancy outcomes such
as delivery of bigger babies and lower prevalence of pre-
term deliveries and maternal anaemia [9].
Antenatal Clinics are considered an important entry point
to target the pregnant women [17,13] as 60–70% of
women attend antenatal clinic at least once during any
pregnancy in Nigeria [13,17]. SP as the drug of choice for
IPTp (IPT-SP) is attractive because its single dose therapy
lends itself for supervised administration in the antenatal
clinic thus ensuring compliance [13].
Implementation of IPT strategy has been established in
many health facilities in malaria endemic areas including
Nigeria. However, it is estimated that less than five percent
of pregnant women have access to effective malaria inter-
ventions; this is worse in the rural areas [20]. A survey car-
ried out in four African countries showed that less than
20% of women use a prophylactic regimen close to the
World Health Organization (WHO) recommendations
[21]. As a result of this poor access, malaria remains one
of the most important causes of maternal and childhood
morbidity in sub-Saharan Africa [1,22].
To date only few studies have investigated factors affecting
adherence to IPTp use [23]. The identified barriers to IPTp
use are related to concerns about SP safety and poor
understanding of the protocol among health care provid-
ers and the community [10]. In a study conducted in Tan-
zania, majority of respondents linked low compliance
with IPTp to poor acceptance of SP because of perceived
association of SP with side effects [17]. It was also
reported that pregnant women throw away drugs after
leaving the clinic. Other factors influencing compliance
include late enrolment, periodic shortages of drugs and
health workers underperformances [23].
Studies related to IPTp use during pregnancy in Nigeria
are limited and none was found to have looked into com-
pliance especially with the directly observed treatment
(DOT) scheme. This study set out to assess IPTp use
among pregnant women attending primary health centers
for antenatal services in a rural area. Their knowledge, atti-
tude towards IPTp use, compliance with IPTp and factors
influencing IPTp use were determined. It was expected
that findings from this study would provide valuableBMC Pregnancy and Childbirth 2009, 9:28 http://www.biomedcentral.com/1471-2393/9/28
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information to guide planning of programmes to improve
the use of IPTp.
Methods
Study area
The study was conducted in Irepodun/Ifelodun local gov-
ernment area (LGA); one of the sixteen LGAs in Ekiti State,
southwest Nigeria. It has a population of approximately
124,088 people who are predominantly Yoruba going by
the provision of 1991 census [24], the major ethnic group
in south western Nigeria. The major occupation of the
inhabitants of the LGA is farming. Most of the women
also engage in petty trading. Malaria is hyper-endemic in
this LGA with perennial transmission. The health pro-
grammes of the local government is planned and man-
aged by the Primary Health Care Department at the LGA
headquarters. The local government area is rural and is
divided into six health districts. There are thirteen health
facilities; twelve primary health care centers which render
antenatal services and one general hospital. Three primary
health centers (PHC) rendering antenatal care are in the
local government headquarter, Igede-Ekiti while one PHC
each is located in nine other towns within the LGA. A
Chief Nursing Officer heads each PHC and is assisted by
staff nurses and community health workers. Antenatal
care services are conducted on Mondays in the three
health centers at the local government headquarters while
the other health centers conduct clinics every Tuesday.
Other activities at each PHC include distribution of free
insecticide treated nets (ITNs) supplied by the Federal
Ministry of Health and immunization.
Study population
The study population comprised all consenting pregnant
women attending antenatal care at all the primary health
centers rendering antenatal services in the study LGA
between July and August, 2007.
Study design and sampling
A cross-sectional design was used. The sample size for the
survey was calculated using estimate of reported IPTp use
among pregnant women (16%) [17]. To detect IPTp use
rate of 5% less or more than the reference rate at 95% con-
fidence interval, the minimum number of pregnant
women required for the study was 207. These were
selected from the antenatal clinic attendees of the twelve
primary health centers (PHCs) rendering antenatal serv-
ices in the LGA using systematic sampling technique. The
sample size was distributed among the PHCs based on
proportionate to size allocation. The total ANC attendants
for the previous one year in each of the facilities were used
for the allocation. Using the estimate of the average clinic
attendance of the month prior to the study, a sampling
interval was determined for each PHC and systematic
sampling was used to select the study subjects. The first
pregnant woman to be interviewed was picked by ballot-
ing from the ANC appointment cards submitted to the
record clerks.
Data collection methods
Information was collected using interviewer-administered
questionnaire, designed by the investigators and pre-
tested prior to use [see Additional file 1]. The question-
naire was written in both English and Yoruba Languages
and was administered by two trained local interviewers
and one of the investigators (SA) in the language the
respondents understood better. The questionnaire com-
prised of questions on socio-demographic characteristics,
obstetric history, knowledge and attitude of pregnant
women to malaria, antenatal clinic use, IPTp use and
mothers' perception of the attitudes and activities of ante-
natal clinic staff.
Ethical consideration
Ethical approval for this study was obtained from the
Joint University of Ibadan/University College Hospital
Institutional Ethics Review Committee. Verbal informed
consent was obtained from each respondent before the
interview.
Data analysis
Data entry and analysis were performed using Statistical
Package for Social Sciences (SPSS) version 13.0 SPSS Inc.,
Chicago, IL, USA. Data was summarized using frequency
tables, graphs, means and standard deviations. Bivariate
analysis was done with chi-square test or Fisher's exact test
to compare proportions for categorical variables. Results
were considered to be significant when the 2-sided value
was < 0.05.
In order to assess the respondents' knowledge on IPTp,
the responses to questions on the definition of IPT were
rated as: 1 (very good) if respondents defined IPT as treat-
ment for prevention of malaria during pregnancy, recog-
nize SP as the drug of choice and the correct interval for
IPT treatment. Respondents were rated 2 (average) if they
knew that IPT was given to prevent malaria during preg-
nancy or that IPT is the use of SP during pregnancy and 3
(poor) if respondent could not define it correctly.
To further investigate the timeliness of ANC attendance, a
categorization of 'early first attendance' was defined as a
first visit to ANC at or before 4 months gestation, and
those registering at fifth month till delivery were consid-
ered as "late first attendance" [25].
Results
Two hundred and nine pregnant women participated in
the study. The mean (SD) age of respondents was 25.1
(1.1) years with a range of 16 to 42 years and 64% in theBMC Pregnancy and Childbirth 2009, 9:28 http://www.biomedcentral.com/1471-2393/9/28
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age group 21–30 years. Many of the respondents
161(77.0%) were "Yoruba", half had secondary school
education, majority, were Christians, 175(83.7%), mar-
ried, 167(79.9%) and of multiple parity. Seventy three
(34.9%), were traders and 53 (25.4%) were unemployed
[Table 1].
Accessibility to PHC centres and time of registration at 
antenatal clinic
One hundred respondents (47.8%) walked to the clinic
and 60 (58.8%) of these spent less than 10 minutes walk-
ing to the clinic. The mean (SD) length of time spent walk-
ing to the ANC was 10.00 (13.2) minutes. Fifty three
(48.6%) of those that did not walk to the clinic spent less
than10 minutes by transport to reach the clinic, mean
(SD) of time spent by them was 15.80 minutes (13.2).
Eighty six (41.1%) respondents spent between N50 and
N100 (50 cents to one dollar – USD) for transportation to
and from the clinic.
The mean (SD) gestational age of respondents at the first
time they visited the clinic was 4.8 (2.15) months. Only
39 (18.7%) of the respondents first registered at the ANC
in the first trimester, 117 (56.0%) did so in the second tri-
mester and 44 (21.0%) in the third trimester. Nine (4.3%)
of them could not remember when they first registered.
When grouped into late and early first attendance,
96(46%) respondents registered early and 113 (54%) reg-
istered late.
Attitude of pregnant women to taking drugs during 
pregnancy
Out of the 209 respondents, 68 (32.5%) mentioned they
were afraid to take drugs in pregnancy, 73 (34.9%) said
there were times they did not take drugs given to them in
the clinic and 108 (51.7%) mentioned they will take
drugs in clinic if allowed to use their own drinking cups.
When those who had heard of IPTp were considered, 44
(40.4%) were afraid of taking drugs in pregnancy, 62
(56.9%) said they did not take drugs given to them in the
clinic and 62 (56.9%) mentioned they will like to do so if
allowed to use their own drinking cups in the clinic.
Table 1: Socio-demographic characteristics of the respondents 
(N = 209)
Variables Frequency Percentages
Age group (years)
16–20 42 20.1
21–25 63 30.1
26–30 71 34.0
31–35 26 12.4
> 35 7 3.3
Level of Education
None 16 7.7
Primary 41 19.6
Secondary 105 50.2
Tertiary 47 22.5
Marital Status
Single 39 18.7
Married 167 79.9
Divorced 2 1.0
Separated 1 0.5
Occupation
Trading/farming 73 34.9
Unemployed 53 25.4
Civil servant 43 20.6
Artisan (e.g hairdresser) 40 19.1
Monthly income
≤ N1000 4 1.9
N1000–N10000 26 12.4
N10000–N20000 16 7.7
> 20000 2 1.0
No sure income 161 77.0
No of pregnancies
1–3 156 74.7
4–6 41 19.6
> 6 1 0.5
No responses 11 5.3
Table 1: Socio-demographic characteristics of the respondents 
(N = 209) (Continued)BMC Pregnancy and Childbirth 2009, 9:28 http://www.biomedcentral.com/1471-2393/9/28
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Knowledge of IPTp
About half [109 (52.2%)] of the respondents, said they
have heard about IPTp. The sources of information on
IPTp are shown in Fig 1. Table 2 shows the rating of
respondents' knowledge of IPTp, drug used, the dose and
timing of IPTp use. Twenty six of the 109 (23.9%) who
have heard about IPTp were able to give a good definition
of IPTp and sixty-three (57.8%) said IPTp can be given to
pregnant women. When asked when IPT drugs can be
given during pregnancy, 67(61.5%) mentioned that it can
be used between 4th and 6th months of pregnancy, 12
(11.0%) mentioned between 7th and 9th months and one
mentioned 1st to 2nd months [Table 2]. About two thirds
of those that have heard of IPTp (73/109; 67.0%) knew
that SP is the recommended drug for IPTp. Using the dif-
ferent brand names of SP in the market, 13(17.8%) iden-
tified Fansidar®, 18(24.7%) identified Amalar®,
42(57.5%) identified Malareich® which was the major
brand given to them in the ANC clinic as drug used for
IPTp. Forty nine (67.1%) of those who mentioned SP
knew the correct dose of SP for IPTp.
IPT use in the index pregnancy
Fifty seven (27.3%) of the 209 respondents reported to
have received at least one dose of IPTp during the index
pregnancy and all were among those who have heard of
IPTp (57/109; 52.3%). No significant difference in knowl-
edge of IPTp was observed among those who had used IPT
and those who did not use IPTp (χ2 = 3.7, p = 0.16).
According to the description of use by respondents, 53
respondents mentioned that three tablets were dispensed
to them, out of which 41 used the three tablets, giving
compliance rate of (77.4%) [Table 3]. Twenty one of the
57 respondents (36.8%) who had received SP in current
pregnancy used it in the ANC of which only three (3/21;
14.3%) were supervised by a health worker at the time of
ingestion. Six out of the 21 (28.6%) that took the drug in
the clinic used the cup provided by the clinic. Twenty two
of the 36 women (61.1%) who did not take their drugs in
the clinic would have liked to do so if allowed to bring
their own drinking cups. Almost half (25/57; 43.9%) of
those who had used IPTp during the index pregnancy
expressed concern about possible adverse effect of SP on
their pregnancies.
Thirty six (63.2%) of those who had received IPTp booked
for antenatal care in the 2nd trimester, 13 (22.8%) in the
1st trimester and 4 (7.0%) in the 3rd trimester. The
remaining four could not say when they first registered for
antenatal care. Only 9 (15.8%) had received the second
dose of IPTp by the time of interview. Pregnant women
who registered in the 1st and 2nd trimester (p = 0.02; χ2 =
10.1; df = 3) and those who were able to define IPTp cor-
rectly (p < 0.001; χ2 = 23.4; df = 2) were significantly more
likely to receive IPTp. The number of women who
received IPTp increased as the number of pregnancies
increased up to the third pregnancy and decreased there-
after (p = 0.01; χ2 = 17.9; df = 7). Majority of the women
116 (77.0%) did not have a sure source of monthly
income. However, 29 out of 48 who volunteered the
amount they earned monthly earned less than N10000
monthly (< $100 USD) and these group of women were
more likely not to use IPTp (p < 0.001; df = 3; χ2 = 2).
There was no significant relationship between gestational
age, age of respondents, and length of time (minutes)
spent trekking to the clinic and IPTp use (p > 0.05).
Discussion
Overall, respondents' knowledge, attitude and practice of
IPTp were poor in this study. Majority did not know sulf-
adoxine-pyrimethamine (SP) as the drug recommended
for IPTp and were not aware that IPTp could be given to
pregnant women. This is unlike findings in a study in Tan-
zania, which reported that pregnant women were gener-
ally aware of SP as the drug recommended for IPTp [17].
Half of the respondents in this study had heard about
IPTp but only a third of these could explain what IPTp is.
However, many of these demonstrated good knowledge
of the drug used, who could be given and when it is given
during pregnancy. In addition many of those who knew
SP as drug for IPTp also knew the correct dose. These find-
ings underscore the need to create more awareness and
improve specific knowledge on IPTp among pregnant
women and those of child bearing age.
The WHO expects 80% of all pregnant women living in
areas of high transmission to receive IPTp during preg-
nancy by 2010 [26]. However, the coverage of the inter-
vention is still low. In Kenya, one of the first countries to
implement IPTp, the national coverage with two doses of
SP was only 4% five years after IPTp implementation [27].
Malawi recorded the highest coverage of 60% close to
achieving the 2000 Abuja target by 2005 [28]. In this
study only 27.3% had received a dose of SP during the
index pregnancy. The probable reason for the low uptake
is the low level of awareness and poor knowledge of IPTp
by the pregnant women. This is supported by the fact that
those who were able to define IPTp correctly in this study
were more likely to have received IPTp at least once.
Worst still regarding IPTp use is the poor adherence to the
recommendations for use. Compliance with the recom-
mendation that IPTp drug should be given under supervi-
sion in the clinic was very low in this study. Only about a
third of the respondents who received IPTp used SP in the
clinic and only three of them were supervised by a health
worker at the time of ingestion, giving a directly observed
therapy (DOT) compliance rate of 14.3%. This low use of
IPTp and poor adherence may not be peculiar to south-BMC Pregnancy and Childbirth 2009, 9:28 http://www.biomedcentral.com/1471-2393/9/28
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west Nigeria alone and the findings in this study may be a
proxy to the practice of IPTp in PHC centres in other parts
of the country. Previous related studies in eastern and
northern Nigeria reported low knowledge of malaria in
pregnancy and management practice as well as poor
maternal health care [22,29].
The reason for poor adherence could be patient or health
worker related. In two cross-sectional studies funded by
the World Health Organization in Muheza district and
Mpwapwa district in Central Tanzania cited by Mubyazi et
al, 2005, low compliance with the use of SP was partly
attributed to health care providers' and users' fear of side
effects of SP and their inadequate knowledge of the cor-
rect dose. Similarly, findings in another study conducted
in Tanzania reported 74% of respondents were said to
have believed that antimalarial drug when taken during
pregnancy could be harmful to the pregnant women and
the unborn children [17]. Mbonye et al. (2006) reported
that pregnant women in Uganda believed that SP is strong
and weakens pregnant women, causes abortions and fetal
abnormalities [30]. In this study, respondents expressed
concern that the drug used for IPTp may cause complica-
tions during pregnancy.
One other user related reason for low compliance was the
unfavorable disposition of the respondents to the use of
cups provided in the clinic. This made them to opt for tak-
ing SP at home. Allowing pregnant women to take the
IPTp drug unsupervised be it at the clinic or at home
makes compliance uncertain and undermines the essence
of IPTp. This practice is probably due to concern about the
quality of water and hygienic use of cups provided in the
clinics as shown in related past studies. For example, in a
study in Tanzania, one of the district medical officers
interviewed opined that the DOT scheme would be effec-
tive if the problem with the shortage of clean water and
sharing of cups in the clinic at peripheral health facilities
was solved. This was alluded to in this study whereby
respondents said they would be willing to take the IPTp
medication in the clinic if they were allowed to bring cups
and water from home. It is also possible that health work-
ers are not well informed about the need to give IPTp
medication supervised or there is laxity in enforcing the
regulation.
Regular availability of SP in the health facility is also crit-
ical to improving the use of IPTp and implementation of
DOT scheme [17]. Sulfadoxine-pyrimethamine for IPTp
in public hospitals in Nigeria was supplied by the Federal
Ministry of Health up to the time of this study. However,
periodic shortages of supply were reported by respond-
ents.
In this study, the health facilities were found to be easily
accessible to the pregnant women, as many of them could
get to the clinic within ten minutes of walking or by public
transport. In addition transport fare was also minimal.
The provision of functional PHCs in every health district
by the LGA is commendable as the easy accessibility is
expected to impact positively on the health of the commu-
nity and be an encouragement for utilization of primary
health centre for antenatal care. However, only half of
respondents in this study were early attendants suggesting
there may be other reasons for the pregnant women not
attending clinic early. A study that compared community
based delivery system for IPTp with IPTp at health units in
area of high transmission in Uganda showed that the
community-based approaches increased access and adher-
ence to IPT with an effect on anemia, severe anemia, par-
asitemia and low birth weight [31]. This could be another
option that could be adopted in addition to improving
level of awareness and knowledge to increase the coverage
of IPTp and adherence.
In this study, the mean (SD) gestational age of respond-
ents as at the first time they visited the clinic was 4.8
(2.15) months. Only about a fifth of the respondents first
attended ANC in the first trimester of gestation, half did so
in the second trimester while another fifth registered in
the third trimester. This is similar to a study carried out in
northern Nigeria whereby 63% registered for ANC in their
2nd trimester [30]. When proportion of early first attend-
ance was considered, the finding was similar to that of a
study in Tanzania which found about half of the women
to have first attended ANC during or before the fourth
month of gestation [25]. This late registration at ANC has
implications for uptake of IPTp. With the late registration
it is unlikely that pregnant women will take the recom-
mended two doses of SP. Late first ANC attendance has
The sources of information on intermittent preventive treat- ment of malaria in pregnancy (IPTp) Figure 1
The sources of information on intermittent preven-
tive treatment of malaria in pregnancy (IPTp).
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Table 2: Respondents Knowledge of IPTp
Variables N = 109
Frequencies Percentages
Definition of IPTp
1 = Very good 26 23.9
2 = Average 15 13.8
3 = Poor 68 62.4
*What drug is recommended for IPTp use
Malareich 42 38.5
Amalar 18 16.5
Phensic 12 11.0
Chloroquine 15 13.8
Fansidar 13 11.9
*Who can be given IPTp
Pregnant Woman 63 57.8
Infants 40 36.7
Aged people 20 18.3
Men 25 22.9
*How many tablets of IPTp is used as a dose
3 tablets 51 46.8
2 tablets 26 23.9
5 tablets 32 . 8
1 tablet 32 . 8
*When is IPTp recommended to be used during pregnancy
4–6 months 67 61.5
7–9 months 12 11.0
1–3 months 10 . 9
Don't Know 25 22.9
* Multiple responsesBMC Pregnancy and Childbirth 2009, 9:28 http://www.biomedcentral.com/1471-2393/9/28
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been identified as an important factor contributing to
incomplete IPT use [27]. The decision that IPTp be admin-
istered through ANC was informed by the expectation that
pregnant women will attend clinic frequently enough to
allow for two doses of SP for IPTp [23]. Although ANC
attendance is high in most countries with IPTp policy
(median, 2.0–4.8 ANC visits per woman) [23], it has not
been sufficient to ensure a high IPTp coverage.
This study was carried out in only one of the 774 LGAs in
Nigeria hence cannot be generalizable. However, it has
provided useful information that can guide policy and
highlighted the need to carry out similar studies in the
other geopolitical zones in the country. This is a hospital-
based study. A community-based study will better capture
knowledge of women who have not been exposed to
health facilities especially antenatal clinic.
Conclusion
The IPTp strategy as currently implemented in this study
area falls short of ensuring that Nigeria achieves the target
of 80% coverage by 2010. These findings highlight issues
to be addressed in order to achieve the target. These
include (i) low level of awareness on IPTp (ii) low uptake
among pregnant women and (iii) poor adherence to the
DOT scheme. Highlighted also in this study are some bar-
riers to IPTp use, which include poor knowledge by
respondents, late enrolment for antenatal care, non-
acceptability of the use of drinking cups provided in clinic
for DOT scheme and periodic shortages of IPTp drugs in
the clinic.
The plausible interventions to address the gaps and defi-
ciencies include developing a health promotion package
to explain the benefits of SP as IPTp agent and to counter-
act the wrong perception that SP could harm both mother
and child. In addition health workers should be provided
continuing education and training to improve their
knowledge about malaria during pregnancy and in partic-
ular IPTp strategy and DOT scheme. Activities of health
workers manning the antenatal clinics should also be
supervised. Special information, communication and
education package to create awareness of the general pub-
lic on the use and safety of SP in pregnancy with efforts to
target special groups like pregnant women and adoles-
cents should be provided.
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